Natural History of Treated Neurocysticercosis and Long-Term Outcomes

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Neurocysticercosis is a brain disease due to the larval stage of the pork tapeworm (Taenia solium). The most common symptoms patient experience from infection inside the substance of the brain (parenchymal disease) are seizures and headaches. When the infection is either inside the fluid pockets inside the brain (ventricular disease) or in the space around the brain (subarachnoid disease) patients can have chronic headaches, relapsing aseptic meningitis, hydrocephalus, stroke, and may require neurosurgical intervention. The purpose of this study is to treat patients with anthelmintic therapy (praziquantel and/or albendazole) and anti-inflammatories in alignment with currently accepted best practices and guidelines, depending on the neurocysticercosis subtype. The purpose of the study is to better understand and characterize clinical, biologic, and management factors during treatment that influence long term outcomes. In order to understand this further we collect patient clinical information, patient survey responses, blood, urine samples, and additional cerebral spinal fluid if already being collected for clinical care....

Eligibility
Participation Requirements
Sex: All
Minimum Age: 3
Maximum Age: 99
Healthy Volunteers: t
View:

⁃ Arms 1-5 (NCC):

• Aged 3 years and older.

• Ability of participant (or legally authorized representative, LAR) to understand and the willingness to sign a written informed consent document.

• Patients with proven or likely NCC

⁃ Arm 6 (Endemic Exposures):

• Patient with epidemiologic history compatible with possible exposure to NCC

• Aged 18 years and older.

Locations
United States
Maryland
National Institutes of Health Clinical Center
RECRUITING
Bethesda
Contact Information
Primary
Perla M Adames Castillo, R.N.
perla.adamescastillo@nih.gov
(301) 402-8495
Backup
Elise M O'Connell, M.D.
oconnellem@mail.nih.gov
(301) 761-5413
Time Frame
Start Date: 1985-10-07
Participants
Target number of participants: 500
Treatments
Arm 1
Subarachnoid (racemose) neurocysticercosis
Arm 2
Ventricular without other viable disease
Arm 3
Parenchymal cyst(s)--non-calcified parenchymal disease at time of referral
Arm 4
Calcified parenchymal disease with symptoms (seizures)
Arm 5
Calcified parenchymal disease without symptoms
Arm 6
Endemic exposure--subjects with compatible epidemiologic exposure to T. solium
Sponsors
Leads: National Institute of Allergy and Infectious Diseases (NIAID)

This content was sourced from clinicaltrials.gov